Cargando…
Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial
BACKGROUND: Idiopathic intracranial hypertension (IIH) is a condition with few effective management options. So far, there have been no randomized controlled trials evaluating new treatments in IIH. OBJECTIVES: The purpose of this paper is to outline the trial design for the Idiopathic Intracranial...
Autores principales: | Markey, Keira Annie, Ottridge, Ryan, Mitchell, James L, Rick, Caroline, Woolley, Rebecca, Ives, Natalie, Nightingale, Peter, Sinclair, Alexandra J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625129/ https://www.ncbi.nlm.nih.gov/pubmed/28923789 http://dx.doi.org/10.2196/resprot.7806 |
Ejemplares similares
-
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension
por: Hardy, Rowan S, et al.
Publicado: (2020) -
Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol
por: Ottridge, Ryan, et al.
Publicado: (2017) -
11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial
por: Markey, Keira, et al.
Publicado: (2020) -
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study
por: Yadav, Yogesh, et al.
Publicado: (2022) -
Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases
por: Markey, Keira A, et al.
Publicado: (2016)